Cornelis M. van Tilburg

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

David S. Hong, Steven G. DuBois, Shivaani Kummar et al. · The Lancet Oncology · 2020 · 955 citations · Full text

Phase 1/2, Surgical Oncology, Tumoral Pathology +9

Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study

Barbara C. Worst, Cornelis M. van Tilburg, Gnana Prakash Balasubramanian et al. · European Journal of Cancer · 2016 · 329 citations · Full text

Health Informatics, Cancer Literacy, Medicine +7

The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets

Cornelis M. van Tilburg, Elke Pfaff, Kristian W. Pajtler et al. · Cancer Discovery · 2021 · 236 citations · Full text

Refined characterization and reference values of the pediatric T- and B-cell compartments

Rogier van Gent, Cornelis M. van Tilburg, Elisabeth E. Nibbelke et al. · Clinical Immunology · 2009 · 177 citations

Pediatric Hematology, Lymphocyte Development, T-regulatory Cell +9

Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors

François Doz, Cornelis M. van Tilburg, Birgit Geoerger et al. · Neuro-Oncology · 2021 · 154 citations · Full text